SeaStar Medical Announces DSMB-Backed Continuation and Expanded Enrollment of Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury Therapy

Reuters

Sep 25

SeaStar Medical Announces DSMB-Backed Continuation and Expanded Enrollment of Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury Therapy

SeaStar Medical Holding Corporation has announced that the independent Data Safety Monitoring Review Board (DSMB) has recommended continuation of the NEUTRALIZE-AKI pivotal trial evaluating the Selective Cytopheretic Device $(SCD)$ therapy in adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). The DSMB reported no device-related safety concerns and identified a signal of potential clinical benefit in the treatment group across key study outcomes. To strengthen statistical power, the DSMB advised increasing total enrollment from 200 to 339 patients. As of the latest update, 137 patients have been enrolled, and study completion is projected near the end of 2026. Results from the trial have not yet been presented, as patient enrollment is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534782-en) on September 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2570802260"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570802260\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570802260?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 04:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570802260","market":"fut","top_or_hot":-1,"title":"SeaStar Medical Announces DSMB-Backed Continuation and Expanded Enrollment of Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SeaStar Medical Announces DSMB-Backed Continuation and Expanded Enrollment of Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICU\">SeaStar Medical Holding Corporation</a> has announced that the independent Data Safety Monitoring Review Board (DSMB) has recommended continuation of the NEUTRALIZE-AKI pivotal trial evaluating the Selective Cytopheretic Device <a href=\"https://laohu8.com/S/SCD\">$(SCD)$</a> therapy in adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). The DSMB reported no device-related safety concerns and identified a signal of potential clinical benefit in the treatment group across key study outcomes. To strengthen statistical power, the DSMB advised increasing total enrollment from 200 to 339 patients. As of the latest update, 137 patients have been enrolled, and study completion is projected near the end of 2026. Results from the trial have not yet been presented, as patient enrollment is ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534782-en) on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SeaStar Medical Announces DSMB-Backed Continuation and Expanded Enrollment of Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeaStar Medical Announces DSMB-Backed Continuation and Expanded Enrollment of Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-25 04:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SeaStar Medical Announces DSMB-Backed Continuation and Expanded Enrollment of Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICU\">SeaStar Medical Holding Corporation</a> has announced that the independent Data Safety Monitoring Review Board (DSMB) has recommended continuation of the NEUTRALIZE-AKI pivotal trial evaluating the Selective Cytopheretic Device <a href=\"https://laohu8.com/S/SCD\">$(SCD)$</a> therapy in adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). The DSMB reported no device-related safety concerns and identified a signal of potential clinical benefit in the treatment group across key study outcomes. To strengthen statistical power, the DSMB advised increasing total enrollment from 200 to 339 patients. As of the latest update, 137 patients have been enrolled, and study completion is projected near the end of 2026. Results from the trial have not yet been presented, as patient enrollment is ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534782-en) on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL6xgXCN:1","article_id":"2570802260","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570802260","pubTimestamp":1758745331,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SeaStar Medical Announces DSMB-Backed Continuation and Expanded Enrollment of Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury Therapy. SeaStar Medical Holding Corporation has announced that the independent Data Safety Monitoring Review Board  has recommended continuation of the NEUTRALIZE-AKI pivotal trial evaluating the Selective Cytopheretic Device  therapy in adult patients with acute kidney injury  requiring continuous renal replacement therapy . The DSMB reported no device-related safety concerns and identified a signal of potential clinical benefit in the treatment group across key study outcomes. To strengthen statistical power, the DSMB advised increasing total enrollment from 200 to 339 patients. As of the latest update, 137 patients have been enrolled, and study completion is projected near the end of 2026. Results from the trial have not yet been presented, as patient enrollment is ongoing.Disclaimer: This news brief was created by Public Technologies  using generative ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","ICU":"SeaStar Medical Holding Corporation","NDAQ":"纳斯达克OMX交易所"},"translate_title":"SeaStar Medical宣布DSMB支持的急性肾损伤治疗关键NEUTRALIZE-AKI试验的继续和扩大入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICU":0.9,"NDAQ":0.9},"content_text":"SeaStar Medical Announces DSMB-Backed Continuation and Expanded Enrollment of Pivotal NEUTRALIZE-AKI Trial for Acute Kidney Injury Therapy\n    \n\nSeaStar Medical Holding Corporation has announced that the independent Data Safety Monitoring Review Board (DSMB) has recommended continuation of the NEUTRALIZE-AKI pivotal trial evaluating the Selective Cytopheretic Device $(SCD)$ therapy in adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). The DSMB reported no device-related safety concerns and identified a signal of potential clinical benefit in the treatment group across key study outcomes. To strengthen statistical power, the DSMB advised increasing total enrollment from 200 to 339 patients. As of the latest update, 137 patients have been enrolled, and study completion is projected near the end of 2026. Results from the trial have not yet been presented, as patient enrollment is ongoing.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534782-en) on September 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}